Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy
Angelo Massimiliano D’Erme,1,2 Marco Romanelli,2 Andrea Chiricozzi2 1Dermatology Unit, Livorno Hospital, Livorno, 2Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy Abstract: Atopic dermatitis (AD) is among the most common inflammatory sk...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-05-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/spotlight-on-dupilumab-in-the-treatment-of-atopic-dermatitis-design-de-peer-reviewed-article-DDDT |
| _version_ | 1817993105482186752 |
|---|---|
| author | D’Erme AM Romanelli M Chiricozzi A |
| author_facet | D’Erme AM Romanelli M Chiricozzi A |
| author_sort | D’Erme AM |
| collection | DOAJ |
| description | Angelo Massimiliano D’Erme,1,2 Marco Romanelli,2 Andrea Chiricozzi2 1Dermatology Unit, Livorno Hospital, Livorno, 2Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy Abstract: Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment is usually based on systemic therapies. The currently available therapeutics are limited, and AD management becomes challenging in most cases. Over the last few years, new advances in the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor α subunit that is able to block the signaling of both IL-4 and IL-13 and achieve rapid and significant improvements in adults with moderate-to-severe AD. Dupilumab is ready to inaugurate a long and promising biological target treatment option for Th2 cell-mediated atopic immune response that characterizes AD. Keywords: dupilumab, atopic dermatitis, eczema, IL-4, IL-13, biologics |
| first_indexed | 2024-04-14T01:34:27Z |
| format | Article |
| id | doaj.art-07bce2fb26e043acabd384b54a500ae0 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-14T01:34:27Z |
| publishDate | 2017-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-07bce2fb26e043acabd384b54a500ae02022-12-22T02:20:00ZengDove Medical PressDrug Design, Development and Therapy1177-88812017-05-01Volume 111473148032835Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapyD’Erme AMRomanelli MChiricozzi AAngelo Massimiliano D’Erme,1,2 Marco Romanelli,2 Andrea Chiricozzi2 1Dermatology Unit, Livorno Hospital, Livorno, 2Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy Abstract: Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment is usually based on systemic therapies. The currently available therapeutics are limited, and AD management becomes challenging in most cases. Over the last few years, new advances in the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor α subunit that is able to block the signaling of both IL-4 and IL-13 and achieve rapid and significant improvements in adults with moderate-to-severe AD. Dupilumab is ready to inaugurate a long and promising biological target treatment option for Th2 cell-mediated atopic immune response that characterizes AD. Keywords: dupilumab, atopic dermatitis, eczema, IL-4, IL-13, biologicshttps://www.dovepress.com/spotlight-on-dupilumab-in-the-treatment-of-atopic-dermatitis-design-de-peer-reviewed-article-DDDTDupilumabatopic dermatitiseczemaIL-4IL-13biologics |
| spellingShingle | D’Erme AM Romanelli M Chiricozzi A Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy Drug Design, Development and Therapy Dupilumab atopic dermatitis eczema IL-4 IL-13 biologics |
| title | Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy |
| title_full | Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy |
| title_fullStr | Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy |
| title_full_unstemmed | Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy |
| title_short | Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy |
| title_sort | spotlight on dupilumab in the treatment of atopic dermatitis design development and potential place in therapy |
| topic | Dupilumab atopic dermatitis eczema IL-4 IL-13 biologics |
| url | https://www.dovepress.com/spotlight-on-dupilumab-in-the-treatment-of-atopic-dermatitis-design-de-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT dermeam spotlightondupilumabinthetreatmentofatopicdermatitisdesigndevelopmentandpotentialplaceintherapy AT romanellim spotlightondupilumabinthetreatmentofatopicdermatitisdesigndevelopmentandpotentialplaceintherapy AT chiricozzia spotlightondupilumabinthetreatmentofatopicdermatitisdesigndevelopmentandpotentialplaceintherapy |